In order to evaluate the clinical implications of HDAC4, we used immunohistochemistry to assess HDAC4 expression in 165 primary tumor tissues from patients with CRC (stage III) and analyzed the relationship between HDAC4 expression and disease-free survival. The gene discussed is HDAC4; the disease is neoplasm.